Published articles

Search collections:

Sort by:	Display results:	Output format:

Published articles	2 records found	Search took 0.08 seconds.

6 p, 754.7 KB

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - DOI (Digital Object Identifier)

10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317

Detailed record -

$A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients$

6 p, 374.8 KB

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients / Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Valladares-Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ; Bando, Inmaculada (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ; Safont, Maria Jose (Hospital General Universitario de Valencia) ; Gallego, Javier (Hospital General Universitario de Elche) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Arrivi, Antonio (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ; Conde, Verónica (Hospital Universitario Virgen de las Nieves (Granada)) ; Ortiz, Maria José (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Alonso, Beatriz (Hospital Universitario de Canarias (La Laguna)) ; Ruiz de Mena, Inmaculada (Spanish Cooperative Group for the Treatment of Digestive Tumours) ; Díaz-Rubio, Eduardo (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Universitat Autònoma de Barcelona
Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patients. [...]
2019 - DOI (Digital Object Identifier)

10.1038/s41416-019-0537-z
British Journal of Cancer, Vol. 121 (july 2019) , p. 378-383

Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.